Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference

VANCOUVER, British Columbia, Oct. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright ... Read More...

Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance

VANCOUVER, British Columbia, Sept. 08, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. ... Read More...

Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

Additions of industry veterans, Dr. Emer Leahy to the Board of Directors and Dr. Tom Lategan as Vice President of Regulatory Affairs, position the Company to advance drug development programsVANCOUVER, British Columbia, June 14, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechno... Read More...